Compass Pathways is trading at $11.83 (5.16%) up today as investors position for the company's Q2 earnings report on August 5, 2026, amid a broader surge in the biotech sector.
- The stock is benefiting from improved risk appetite across U.S. equities, with the biotech sector gaining more than 2% today.
- Investors are closely monitoring the upcoming financial results and the company’s progress regarding its rolling NDA submission for COMP360.